Pixium Vision SA of France has raised €34.5 million with an initial public offering of its shares on the Euronext stock exchange in Paris. The proceeds will be used to advance two products that aim to treat blindness caused by a degeneration of photoreceptor cells in the retina.
Cardio3 BioSciences SA of Belgium is to sell shares valued at €25 million to Medisun International Ltd of Hong Kong in a two-part deal that will also see it participate in a joint venture with
Abzena Ltd, which provides services to companies developing biopharmaceuticals, said it intends to make an initial public offering of its shares on the Alternative Investment Market of the London Stock Exchange. Financial details have not yet been disclosed.
A nanoparticle designed to treat soft tissue sarcoma has passed its first hurdle with the successful conclusion of a Phase 1 study in patients with the disease. The developer, Nanobiotix SA, plans to position the product alongside radiotherapy as a treatment for patients with locally advanced sarcoma for whom few treatment options exist.
A Phase 3 trial of the antibody therapeutic Cyramza (ramucirumab) has failed to reach its primary endpoint of overall survival in patients with liver cancer. The trial was comparing Cyramza plus best supportive care to placebo plus best supportive care as a second-line therapy.
MorphoSys AG and Merck Serono have become the latest companies to collaborate on potential treatments for cancer that modulate the immune system’s natural ability to fight tumours. Together they will discover and develop therapeutic antibodies against undisclosed immune checkpoints.
Synairgen Plc of the UK has outlicensed an experimental compound for severe asthma to AstraZeneca Plc for an upfront fee of $7.25 million and potential development, regulatory and commercial milestones of up to $225 million.
Autifony Therapeutics Ltd, a 2011 spin-out from GlaxoSmithKline Plc with technology to treat hearing disorders, has received £2.2 million in grant funding from UK Technology Strategy Board.
Christopher Viehbacher, the chief executive of Sanofi SA, has decided to move from Paris, France to Boston, Massachusetts, US, the home of the company’s biotechnology subsidiary Genzyme. The decision was first reported in Le Monde on 3 June and later confirmed by the company.
A UK-based service provider, BioSilta Ltd, has raised €2.5 million from its founding investor and the new investor Omega Funds in order to support the commercial expansion of its reagent-based growth systems for bacterial cultures.